Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells

Koya, Yoshihiro; Liu, Wenting; Yamakita, Yoshihiko; Senga, Takeshi; Shibata, Kiyosumi; Yamashita, Mamoru; Nawa, Akihiro; Kikkawa, Fumitaka; Kajiyama, Hiroaki

doi:10.18632/oncotarget.25975

Cited by 13 publications

(18 citation statements)

References 62 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The penetrance frequency and fold changes of HCLS1 were high in these cases. Previously, it has been observed to be upregulated in several cancers, and its expression level is associated with increased cell migration, metastasis, and poor prognosis [47]. However, we cannot find its association with beta-thal major patients in literature; in the future, this association needs to be explored with a large dataset.…”

Section: Discussionmentioning

confidence: 74%

A Novel Method to Identify Autoantibodies against Putative Target Proteins in Serum from beta-Thalassemia Major: A Pilot Study

Sumera

Anuar²,

Radhakrishnan

et al. 2020

Biomedicines

View full text Add to dashboard Cite

Abnormal immune reactivity in patients with beta-thalassemia (beta-thal) major can be associated with poor prognosis. Immunome protein-array analysis represents a powerful approach to identify novel biomarkers. The Sengenics Immunome Protein Array platform was used for high-throughput quantification of autoantibodies in 12 serum samples collected from nine beta-thal major patients and three non-thalassemia controls, which were run together with two pooled normal sera (Sengenics Internal QC samples). To obtain more accurate and reliable results, the evaluation of the biological relevance of the shortlisted biomarkers was analyzed using an Open Target Platform online database. Elevated autoantibodies directed against 23 autoantigens on the immunome array were identified and analyzed using a penetrance fold change-based bioinformatics method. Understanding the autoantibody profile of beta-thal major patients would help to further understand the pathogenesis of the disease. The identified autoantigens may serve as potential biomarkers for the prognosis of beta-thal major.

show abstract

Section: Discussionmentioning

confidence: 74%

A Novel Method to Identify Autoantibodies against Putative Target Proteins in Serum from beta-Thalassemia Major: A Pilot Study

Sumera

Anuar²,

Radhakrishnan

et al. 2020

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Immunoblot analysis was performed to detect MITF antigens in clinical samples and cell lines, as described previously [ 57 ]. The antibodies (Abs) utilized were anti-MITF, C5 (Santa Cruz Biotechnology, Dallas, TX, USA), E-cadherin (CST, Tokyo, Japan), N-cadherin (BD Biosciences, Tokyo, Japan), vimentin (Santa Cruz Biotechnology), and anti-GAPDH (CST).…”

Section: Methodsmentioning

confidence: 99%

Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer

Kitami

Yoshihara

Koya

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

Ovarian cancer (OvCa) is one of the leading causes of death due to its high metastasis rate to the peritoneum. Recurrent peritoneal tumors also develop despite the use of conventional platinum-based chemotherapies. Therefore, it is still important to explore the factors associated with peritoneal metastasis, as these predict the prognosis of patients with OvCa. In this study, we investigated the function of microphthalmia-associated transcription factor (MITF), which contributes to the development of melanoma, in epithelial ovarian cancer (OvCa). High MITF expression was significantly associated with a poor prognosis in OvCa. Notably, MITF contributed to the motility and invasion of OvCa cells, and specifically with their peri-mesothelial migration. In addition, MITF-positive cells expressed the melanoma cell adhesion molecule (MCAM/CD146), which was initially identified as a marker of melanoma progression and metastasis, and MCAM expression was regulated by MITF. MCAM was also identified as a significant prognostic factor for poor progression-free survival in patients with OvCa. Collectively, our results suggest that MITF is a novel therapeutic target that potentially promotes peritoneal metastasis of OvCa.

show abstract

“…In contrast, tumor suppressor genes including IGFBP3 59 , RGS4 60 , RGS5 61 , IFI16 62 and EPHA5 63 were overexpressed, and SORBS2 (ArgBP2) 64,65 , MARVELD3 66 and CXADR 67 were downregulated in PAR2-KO PC3 cells. Tumor promoter genes such as SPARC 68 , BST2 69 , HCLS1 70 and TSPAN8 71 genes were upregulated PAR2-KO PC3, while CADPS2 72,73 , CALB1 74 , CCNA1 75 , TMPRSS15 76 , SYK 77 , CEACAM5 78 and C3 79,80 genes that are overexpressed in metastasis were significantly downregulated. Overall, this suggests that PAR1 and PAR2 regulate both tumor promoting and suppressing roles by regulating several key oncogenes associated with PCa.…”

Section: Differentially Expressed Genes In Par1-ko and Par2-ko Pc3 Cellsmentioning

confidence: 99%

Autocrine Proteinase Activated Receptor (PAR) mediated signaling in prostate cancer cells

Chandrabalan

Ramachandran

2022

Preprint

View full text Add to dashboard Cite

Proteinase activated receptors (PARs) are G protein-coupled receptors (GPCRs) activated by limited N-terminal proteolysis. A variety of proteolytic enzymes derived from the coagulation cascade and inflammatory milieu activate PARs, however specific activators in different physiological and pathophysiological contexts remain poorly defined. PARs are highly expressed in many cancer cells and regulate various aspects of tumor growth and metastasis. Endogenous proteinases that regulate PARs in the setting of various tumors however remains unresolved. Prostate cancer (PCa) remains a major cause of mortality in men despite advances in early detection and clinical intervention. PAR expression has been reported in PCa, however, their role here remains poorly defined. In androgen independent PC3 cells, we find functional expression of PAR1 and PAR2 but not PAR4. Using genetically encoded PAR cleavage biosensors, we find that PCa cells secrete proteolytic enzymes that cleave PARs and trigger autocrine signaling. Deletion of PAR1 and PAR2 using CRISPR/Cas9 combined with microarray analysis revealed genes that are differentially regulated by this autocrine signalling mechanism. Interestingly, several genes that are known PCa prognostic factors or biomarker were differentially expressed in PAR1-KO and PAR2-KO PC3 cells. We also examined PAR1 and PAR2 regulation of PCa cell proliferation and migration using PAR1 and PAR2-KO PC3 cells, as well as PAR1 and PAR2 specific agonists and antagonists. We find that PAR1 and PAR2 have opposite effects on PC3 cell proliferation and migration. In summary, we have identified an autocrine signaling mechanism through PARs as a regulator of PCa cell function.

show abstract

Hematopoietic lineage cell-specific protein 1 (HS1), a hidden player in migration, invasion, and tumor formation, is over-expressed in ovarian carcinoma cells

Cited by 13 publications

References 62 publications

A Novel Method to Identify Autoantibodies against Putative Target Proteins in Serum from beta-Thalassemia Major: A Pilot Study

A Novel Method to Identify Autoantibodies against Putative Target Proteins in Serum from beta-Thalassemia Major: A Pilot Study

Microphthalmia-Associated Transcription Factor-Dependent Melanoma Cell Adhesion Molecule Activation Promotes Peritoneal Metastasis of Ovarian Cancer

Autocrine Proteinase Activated Receptor (PAR) mediated signaling in prostate cancer cells

Contact Info

Product

Resources

About